Search

York University's Centre for Novel Agricultural Products has won a grant from the Bill & Melinda Gates Foundation to complete research into an antimalarial plant.

With the end of easy oil, French oil services giant Schlumberger Clamart Technology Centre is transforming its research and development activities.

Novartis’s move to take over UK biotech NeuTec Pharma at a large premium highlights how the so-called “superbugs” have reinvigorated pharma’s interest in antibiotics.

Carlos Moreira, co-founder and chairman of Swiss data-encryption firm WISekey, talks to Science|Business editor Richard L. Hudson on the travails of entrepreneurship.

Civo BioScreening is looking for strategic partnerships to help it take forward its novel polymer screening technology.

Innate Pharma SA has applied for an initial public offering and listing on the Euronext in Paris, to raise funds to expand its pipeline of oncology therapeutics.

Wine and biotechnology come together in yet another genome project.

The University of Manchester is launching a £10 million research centre for developing sustainable energy technologies.

European Union has voted to continue funding embryonic stem cell research after a heated debate at the European Parliament on Tuesday.

Cuts in federal funding have forced UC Berkeley's RAD Lab to seek industry funding. But the money may not be enough to plug the gap.

The future of European Union funded embryonic stem cell research hangs in the balance after a heated debate at the European Parliament on Tuesday.

Indian firms are training large numbers of patent agents - with their eye on the large number of companies abroad looking for cheaper patenting.

Software agents could change the way that computing works. You just leave them to get on with the work.

Universities in Ireland can now bid for funds to beef up their knowledge transfer activities.

In an earlier blog, I deplored the lack of data about the European IP market and in particular about the academic licensing business. I am delighted to report that my “bottle in the ocean” approach has produced results.

Advances in neuroscience are opening up the treatment options for central nervous system diseases - at the same time as the ageing population is increasing the market for these products.

The Open Source software movement has broken the stranglehold of expensive, proprietary products. Could the same thing happen in biotechnology?

A group of researchers, led by Mark Pepys, at University College London has designed and chemically synthesised a new drug, which they have shown to reduce heart tissue damage following a heart attack.

Scientists from the University of Birmingham, UK, have powered a fuel cell from confectionary waste. They now want to form a consortium with investors and SMEs to apply for an EU Framework grant.

A laser physicist in Saudi Arabia has devised a workable optical diagnostic tool to detect early cancer - and is now looking for partners to commercialise the technology.